Joshua Jennings
Stock Analyst at TD Cowen
(3.16)
# 926
Out of 4,827 analysts
68
Total ratings
41.27%
Success rate
2.67%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVR Anteris Technologies Global | Initiates: Buy | $15 | $4.38 | +242.47% | 1 | Jan 7, 2025 | |
| PODD Insulet | Maintains: Buy | $264 → $324 | $257.00 | +26.07% | 1 | Jan 3, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $100 → $110 | $103.29 | +6.50% | 7 | Dec 12, 2024 | |
| CBLL CeriBell | Maintains: Buy | $31 → $36 | $17.10 | +110.53% | 2 | Dec 9, 2024 | |
| TMDX TransMedics Group | Maintains: Buy | $175 → $120 | $93.20 | +28.76% | 9 | Nov 18, 2024 | |
| HUMA Humacyte | Reiterates: Buy | $10 | $1.21 | +726.45% | 2 | Oct 18, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $50 | $2.36 | +2,018.64% | 1 | Oct 2, 2024 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $75 → $99 | $54.81 | +80.62% | 3 | Sep 16, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Hold | $143 → $119 | $95.11 | +25.12% | 1 | Sep 6, 2024 | |
| VCEL Vericel | Maintains: Buy | $55 → $60 | $41.87 | +43.30% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $81.82 | -2.22% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $15.88 | +183.38% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $100 → $70 | $74.63 | -6.20% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $185 | $155.66 | +18.85% | 1 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $31.20 | +28.21% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $382.46 | +4.59% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $34.80 | +72.41% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $22.74 | +49.52% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $4.98 | +261.45% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $114 → $125 | $85.34 | +46.47% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $17.46 | +43.18% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $134.00 | -2.99% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $2.16 | +131.48% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $83.62 | +39.92% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $450 | $8.84 | +4,990.50% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $12.74 | -5.81% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $167.95 | +63.74% | 1 | Feb 7, 2020 |
Anteris Technologies Global
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $4.38
Upside: +242.47%
Insulet
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $257.00
Upside: +26.07%
Boston Scientific
Dec 12, 2024
Maintains: Buy
Price Target: $100 → $110
Current: $103.29
Upside: +6.50%
CeriBell
Dec 9, 2024
Maintains: Buy
Price Target: $31 → $36
Current: $17.10
Upside: +110.53%
TransMedics Group
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $93.20
Upside: +28.76%
Humacyte
Oct 18, 2024
Reiterates: Buy
Price Target: $10
Current: $1.21
Upside: +726.45%
Allurion Technologies
Oct 2, 2024
Initiates: Buy
Price Target: $50
Current: $2.36
Upside: +2,018.64%
PROCEPT BioRobotics
Sep 16, 2024
Maintains: Buy
Price Target: $75 → $99
Current: $54.81
Upside: +80.62%
Zimmer Biomet Holdings
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $95.11
Upside: +25.12%
Vericel
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $41.87
Upside: +43.30%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $81.82
Upside: -2.22%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $15.88
Upside: +183.38%
Jul 25, 2024
Downgrades: Hold
Price Target: $100 → $70
Current: $74.63
Upside: -6.20%
Jul 18, 2024
Maintains: Buy
Price Target: $195 → $185
Current: $155.66
Upside: +18.85%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $31.20
Upside: +28.21%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $382.46
Upside: +4.59%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $34.80
Upside: +72.41%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $22.74
Upside: +49.52%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $4.98
Upside: +261.45%
Feb 10, 2023
Maintains: Outperform
Price Target: $114 → $125
Current: $85.34
Upside: +46.47%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $17.46
Upside: +43.18%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $134.00
Upside: -2.99%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $2.16
Upside: +131.48%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $83.62
Upside: +39.92%
Dec 7, 2021
Initiates: Outperform
Price Target: $450
Current: $8.84
Upside: +4,990.50%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $12.74
Upside: -5.81%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $167.95
Upside: +63.74%